KORRO BIO INC (KRRO) — insider trading
Health Care · NASDAQ
KORRO BIO INC (KRRO) has 22 reported SEC Form 4 insider transactions in our data, including 16 open-market sales among the most recent 22 (latest 2026-07-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | Chappell Todd | Officer (Chief Operating Officer) | Grant / award / vesting | 7,500 | $0.00 | $0 | Form 4 |
| 2026-07-15 | Cerio Jeffrey | Officer (General Counsel) | Grant / award / vesting | 6,500 | $0.00 | $0 | Form 4 |
| 2026-07-15 | Dolan Oliver | Officer (Senior Vice President, Finance) | Grant / award / vesting | 5,500 | $0.00 | $0 | Form 4 |
| 2026-07-15 | Vincent Loic A | Officer (Chief Scientific Officer) | Grant / award / vesting | 7,500 | $0.00 | $0 | Form 4 |
| 2026-07-06 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 8,506 | $13.96 | $118.7K | Form 4 |
| 2026-07-06 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 817 | $13.96 | $11.4K | Form 4 |
| 2026-07-02 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 14,745 | $14.03 | $206.9K | Form 4 |
| 2026-07-02 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 85,955 | $14.03 | $1.21M | Form 4 |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 114 | $14.98 | $1.7K | Form 4 |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 6,979 | $14.60 | $101.9K | Form 4 |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 666 | $14.98 | $10.0K | Form 4 |
| 2026-06-24 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 40,679 | $14.60 | $593.9K | Form 4 |
| 2026-06-23 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 17,426 | $14.25 | $248.3K | Form 4 |
| 2026-06-23 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 101,579 | $14.25 | $1.45M | Form 4 |
| 2026-06-22 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 580 | $13.95 | $8.1K | Form 4 |
| 2026-06-22 | FORMELA JEAN FRANCOIS | Director | Open-market sale | 3,382 | $13.95 | $47.2K | Form 4 |
| 2026-06-16 | Dolan Oliver | Officer (Senior Vice President, Finance) | Open-market sale | 3,383 | $10.83 | $36.6K | Form 4 |
| 2026-06-16 | Cerio Jeffrey | Officer (General Counsel) | Open-market sale | 6,609 | $10.83 | $71.6K | Form 4 |
| 2026-06-16 | Vincent Loic A | Officer (Chief Scientific Officer) | Open-market sale | 3,418 | $10.83 | $37.0K | Form 4 |
| 2026-06-16 | Chappell Todd | Officer (Chief Operating Officer) | Open-market sale | 3,168 | $10.83 | $34.3K | Form 4 |
| 2026-06-10 | Meyers Rachel | Director | Grant / award / vesting (derivative) | 14,677 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Behbahani Ali | Director | Grant / award / vesting (derivative) | 14,677 | $0.00 | $0 | Form 4 |
Ask the chat about KRRO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KORRO BIO INC (KRRO).
Last updated 2026-07-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.